Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I/ Phase II
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients
Details : Regadenoson is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Myocardial Ischemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 27, 2020
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lexiscan is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cardiovascular Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 06, 2017
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
Details : Regadenoson is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Graft Rejection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 05, 2015
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
Details : Regadenoson is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure, Diastolic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 28, 2015
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension
Details : Regadenoson is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypertension, Pulmonary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 20, 2014
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking
Details : Regadenoson is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Ischemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 05, 2014
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Stress CT Perfusion in Patients With Chest Pain
Details : Regadenoson is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Coronary Artery Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 25, 2013
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Regadenoson is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Coronary Artery Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2013
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Regadenoson is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2013
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects
Details : Regadenoson is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 08, 2013
Lead Product(s) : Regadenoson Monohydrate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable